Effects of Polyphenol Containing Antioxidants on Oxidative Stress in Diabetic Patients

NCT ID: NCT00682149

Last Updated: 2008-05-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-05-31

Study Completion Date

2008-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There has been an increase in the prevalance of type 2 diabetes in developed countries in recent years. The major contributing factors have been genetic predisposition, environmental factors, and unhealthy eating habits and stress. Adverse effects on cardiovascular and renal systems after prolonged hyperglycemia bring serious burden to patients, to their families and to the society.

Oxidative stress has been defined as the imbalance between the production of reactive oxygen molecules and antioxidant protective molecules. It has been claimed that oxidative stress that the organism is exposed to and disturbance in anti-oxidant mechanisms have been important in the initiation of diabetes and its complications. Malondialdehyde is the final product of lipid peroxidation and it is an aldehyde as well. It has been accepted that malondialdehyde has been a biomarker in measuring oxidative stress.

Type 2 diabetic people who are between 40 -65 years of age will be the subjects of our study. The levels of fasting glucose, HbA1c, LDL, triglyceride, AST and ALT and also malondialdehyte, hydrogen peroxide and oxidative stress will be determined in patients blood after making them consume a 1500 calory standard diet for 2 weeks, The patients will be randomly divided into two grouos at the end of the two weeks. Group 1 will take placebo in addition to the diet, Group 2 will receive polyphenol containing capsules with pomegranate extract (500 mg), green tea extract (300 mg) and a little bit of (60 mg) vitamin C for three months. At the end of three months the measurement of biochemical parameters will be repeated.

Patients with cardiac, renal, liver disease and smokers will be excluded from the study.

Patients in both groups will have a diet rich in vegetables, three servings of fruit, maximum three slices of bread with a total calory of 1500.

In addition to these, both groups will have a weekly aerobic exercise regimen of 150 minutes conducted after breakfast.

The biochemical results of the two groups will be compared at the end of the experiment and they will be statistically evaluated.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Oxidative stress malondialdehyde glutathione diabetes polyphenol containing antioxidants diet rich in vegetables weekly aerobic exercise

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

We planned to compare a study group of 60 subjects with a placebo group of 60 subjects

Group Type PLACEBO_COMPARATOR

PomGT (500 mg pomegranate extracts, 300 mg green tea and 60mg vitamin C)

Intervention Type DIETARY_SUPPLEMENT

1 tablet/day for 3 months

Group 2

We planned to compare a study group of 60 subjects with a placebo group of 60 subjects

Group Type ACTIVE_COMPARATOR

PomGT (500 mg pomegranate extracts, 300 mg green tea and 60mg vitamin C)

Intervention Type DIETARY_SUPPLEMENT

1 tablet/day for 3 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PomGT (500 mg pomegranate extracts, 300 mg green tea and 60mg vitamin C)

1 tablet/day for 3 months

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Comilac PomGT tablets

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Type 2 diabetic patients between 40-65 years of age will be eligible for the study

Exclusion Criteria

* Patients with cardiac, renal, liver disease and smokers will be excluded from the study.
Minimum Eligible Age

40 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Yeditepe University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Yeditepe University Medical Faculty, Family Medicine Department

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Aysen Fenercioglu, Assist Prof. Dr.

Role: PRINCIPAL_INVESTIGATOR

Yeditepe University Medical Faculty, Family medicine Department

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sisli Etfal Education and Research Hospital

Istanbul, , Turkey (Türkiye)

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Aysen Fenercioglu, Assist Prof Dr.

Role: CONTACT

Phone: (+90 537) 9645751

Email: [email protected]

Ece Genc, Prof. Dr.

Role: CONTACT

Phone: (+90 535) 2178145

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Tayyibe Saler, Dr

Role: primary

Aysen Fenercioglu, Assist Prof. Dr.

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DM2-AOC

Identifier Type: -

Identifier Source: org_study_id